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Abstract
Tuberous Sclerosis Complex (TSC) is an autosomal dominant tumor suppressor gene syn-
drome in which patients develop several types of tumors, including facial angiofibroma, sub-
ungual fibroma, Shagreen patch, angiomyolipomas, and lymphangioleiomyomatosis. It is
due to inactivating mutations in TSC1 or TSC2. We sought to generate a mouse model of
one or more of these tumor types by targeting deletion of the Tsc1 gene to fibroblasts using
the Fsp-Cre allele. Mutant, Tsc1ccFsp-Cre+ mice survived a median of nearly a year, and
developed tumors in multiple sites but did not develop angiomyolipoma or lymphangioleio-
myomatosis. They did develop a prominent skin phenotype with marked thickening of the
dermis with accumulation of mast cells, that was minimally responsive to systemic rapamy-
cin therapy, and was quite different from the pathology seen in human TSC skin lesions.
Recombination and loss of Tsc1 was demonstrated in skin fibroblasts in vivo and in cultured
skin fibroblasts. Loss of Tsc1 in fibroblasts in mice does not lead to a model of angiomyoli-
poma or lymphangioleiomyomatosis.
Introduction
Tuberous Sclerosis Complex (TSC) is an autosomal dominant genetic disorder due to inacti-
vating mutations in either TSC1 or TSC2. There are well-established consensus diagnostic cri-
teria for TSC; the major clinical criteria include angiofibromas or fibrous cephalic plaque,
ungual fibromas, shagreen patch, angiomyolipomas, and lymphangioleiomyomatosis [1].
Tumors that develop in TSC are known to develop through a two hit mechanism, in which
there is uniform germ-line or mosaic inactivating mutation in TSC1 or TSC2, and second hit
inactivating mutation in the other allele of the same gene to lead to loss of function of either
TSC1 or TSC2 in the cells comprising the tumor [2–8]. Similar findings have been made in the
majority of sporadic angiomyolipoma and lymphangioleiomyomatosis lesions [3–5, 8].
Heretofore no mouse model has been generated which replicates the core features of any of
these TSC tumors, including angiofibromas, ungual fibromas, shagreen patch, angiomyolipo-
mas, or lymphangioleiomyomatosis. Here we sought to generate such a model by targeting bi-
allelic deletion of Tsc1 to fibroblasts. Fibroblasts or a closely related cell type are thought to be
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the cell which gives rise to angiofibromas, ungual fibromas, and shagreen patch [2], and might
be the cell which gives rise to angiomyolipoma and lymphangioleiomyomatosis.
Materials and Methods
Mice and drug treatments
All procedures were carried out in accordance with the Guide for the Humane Use and Care
of Laboratory Animals, and the study was approved by the Animal Care and Use Committee
of Children’s Hospital, Boston. The approved protocol contained the following procedures.
Euthanasia was performed using CO2 narcosis. Mice were monitored 3 times per week. If any
of the following conditions occurred mice were subject to euthanasia: skin irritation or break-
down, tumors > 10% body weight, tumors that limit mobility, lethargy, loss of appetite, weight
loss > 15–20%, Rodent Body Condition Score of 1 or 2. Some of the Tsc1ccFsp-cre+ mice were
subject to euthanasia for these reasons. None died spontaneously. Some mice were treated
with Baytril cream for dermatitis to alleviate suffering, but anesthetics, analgesics, or other
treatments were not used. Mice were housed under standard conditions meeting the standards
of the Guide for the Humane Use and Care of Laboratory Animals, with strict cage crowding
limits, a temperature of 70˚F and a 12 hour light/dark cycle.
Tsc1 conditional allele mice, denoted Tsc1cc were originally derived in this laboratory [9]
(c denotes conditional, floxed allele; w denotes wild type allele). Mice with the Fsp-Cre allele
were a generous gift of Gustavo Leone, Ohio State University, and were described in [10]. In
these mice, Cre expression is driven by a 3.1-kb gene promoter sequence extending from 1.9
kb upstream of exon 1 to the end of intron 1 of the S100A4 gene (formerly known as Fibroblast
specific protein1, or Fsp1). Mice were derived by standard breeding strategies. Tsc1ccFsp-cre+
mice were compared to Tsc1cwFsp-cre+, Tsc1cc, and Tsc1cw mice.
DNA was prepared from mouse toes/tails by standard procedures for genotyping. PCR gen-
otyping for Tsc1 was performed using a three-primer system that allows simultaneous analysis
of wildtype (w), conditional (c), and knockout (k) alleles, followed by agarose gel electrophore-
sis [9]. Primers that amplify a 300 bp portion of the cre recombinase were used to assess the
presence of the Fsp-cre allele.
Rapamycin was purchased from LC laboratories (Woburn, MA). A 20 mg/ml stock was
made using ethanol, and mixed daily for injection with sterile vehicle (0.25% PEG-200, 0.25%
Tween-80). Mice were treated with rapamycin by intraperitoneal (IP) injection at 3 mg/kg
three times per week for four weeks. Control mice received the vehicle solution IP on the same
schedule.
Pathology studies
Six micrometer sections were prepared from tissues fixed with 10% formalin overnight fol-
lowed by 70% ethanol and paraffin embedding, and stained with hematoxylin and eosin by
standard techniques at the Rodent Pathology Core at Harvard Medical School.
Skin samples were collected from both ventral and dorsal mouse skin. Skin thickness was
quantified by a dermatopathologist (SG) who was blinded to the genotype of the mice. Multi-
ple regions across a single long biopsy of skin were examined and measured at three distinct
sites, and averaged to determine the skin epidermal and dermal thickness for each mouse.
Chloroacetate esterase staining of skin sections was performed to identify mast cells. Sections
were deparaffinized with xylene, put through an alcohol series, treated with Napthol AS-D
chloroacetate esterase (Sigma) and counterstained with hematoxylin. Mast cells per high pow-
ered field (400x) were quantified in a blinded manner by a dermatopathologist (SG).
TSC Skin Model
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For immunofluorescence studies, ventral skin samples were flash frozen in OCT, cut in 5
micron sections, blocked in PBS with 10% milk, and incubated with anti-pS6 (S235/S236)
(CST, at 1:100 dilution) and anti-Cre (CST, at 1:800 dilution) antibodies. Secondary antibodies
were also obtained from CST, and were conjugated with Alexa-488 and Alexa-555 fluorophore
(used at 1:500 dilution). Slides were mounted using ProLong Gold Antifade with DAPI (cat#
P36941, Thermo). Sections were viewed using a Fluoview FV10i (Olympus) confocal micro-
scope and analyzed using ImageJ (National Institutes of Health) software.
Primary fibroblast cell culture and immunoblotting
Fibroblast cell lines were derived from the skin of mouse pups of age P0-P7 from a breeding of
Tsc1ccFsp-cre+ x Tsc1cc mice. After euthanasia, and 70% ethanol sterilization, skin samples
(1cm x 1cm) were collected from the underarm or abdominal areas. Skin samples were washed
again in 70% ethanol and then washed in PBS. They were cut into small pieces, treated with
0.2% collagenase (Sigma) in serum-free Ham’s F-12 media (Invitrogen) at 37˚C for 1hr, with
agitation every 20 min. The cells were washed with PBS 3 times, plated in fibroblast culture
medium, and maintained in an incubator at 37˚C with 5% CO2. Fibroblast culture medium is
a 1:1 mix of DMEM and F-12 (Invitrogen) containing 15% FBS (Invitrogen), 1% HEPES buffer
solution (GIBCO), 1% nonessential amino acid mixture (GIBCO), 1% L-glutamine (GIBCO),
1% penicillin/streptomycin (Cellgro) and 1% sodium pyruvate (GIBCO). For serum starva-
tion, cells were cultured in the absence of serum for 24 h.
Cells were harvested in lysis buffer consisting of 50 mM Tris-HCl (pH 7.5), 150 mM NaCl,
1% Triton X-100, 1 mM EDTA, 1 mM EGTA and a cocktail of protease inhibitors (Sigma-
Aldrich, St. Louis, MO). Cell lysates were clarified by centrifugation for 5 min at 14k rpm, and
the protein concentration of the supernatants was determined using a modified Bradford assay
(Bio-Rad, Hercules, CA). For immunoblotting, 10 μg of protein was loaded in each lane, and
was separated by SDS-PAGE on 4–12% gradient gels (Invitrogen, Carlsbad, California), trans-
ferred to PVDF membranes and detected by immunoblotting with the following primary
antibodies: TSC1, TSC2, pAKT(S473), AKT, pS6(S240/244), S6, pS6K1(Thr389), pS6K1, and
actin (all from Cell Signaling Technology; all used at 1:1,000 dilution, except for actin, used at
1:15,000). Goat anti-mouse and anti-rabbit secondary antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA) conjugated to horseradish peroxidase were used at a 1:3000 dilution and
immunoreactive bands were detected by chemiluminescence (SuperSignal, Pierce, Rockford,
IL) and film (Denville Scientific, South Plainfield, NJ).
Statistical analysis
All data points are shown in relevant figures as dot plots. Average values are indicated by a
horizontal line. P values were calculated using GraphPad Prism v7.0a using the Mann-Whit-
ney test.
Results
Fsp-cre mediated loss of Tsc1 leads to multiple phenotypes including
premature mortality
To attempt to develop a mouse model of Shagreen patch, cephalic patch, facial angiofibroma,
ungual fibroma, renal angiomyolipoma, and/or lymphangioleiomyomatosis, we used an Fsp-
cre transgene [10] to drive loss of Tsc1 in fibroblasts in mice in vivo. Through initial breeding
experiments we found that Tsc1ccFsp-cre+ mice were generated at Mendelian ratios, displayed
no unusual mortality through the age of 6 months, and that both sexes were fertile. However,
TSC Skin Model
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Tsc1ccFsp-cre+ mice began to die at 6 months and had a median survival of 338 days in contrast
to Tsc1cwFsp-cre+ and Tsc1cc littermates (Fig 1A, p< 0.0001). Male and female Tsc1ccFsp-cre+
mice showed a similar reduction in survival (Fig 1A right). However, female Tsc1ccFsp-cre+
mice all died due to the development of chylous ascites, while male Tsc1ccFsp-cre+ mice died of
sudden death. Tsc1ccFsp-cre+ mice (n = 12; 4 males, 8 females; age 9–14 months) displayed
multiple findings at necropsy including osteopetrosis (100%), liver hemangioma (67%),
hyperplastic vessels (33%) and uterine rhabdomyosarcoma (88% in females). Other findings
included stomach adenoma, lung adenoma, lung thrombus, thymic atrophy, ear angioma, and
aortic angioma (intraluminal). However, there was no evidence of angiomyolipoma in the kid-
neys or other organs of these mice. Nor were any pulmonary lesions or cystic lung disease
identified.
Hence we focused on the skin manifestations seen in the Tsc1ccFsp-cre+ mice.
Tsc1ccFspCre+ mice have a major skin phenotype
A clear and universal phenotype observed in the Tsc1ccFsp-cre+ mice was the development of
loose, apparently excessive skin on both the dorsal and ventral surfaces (Fig 1B and 1C). This
appeared by one month of age, and was a reliable marker of genotype in all mice. Tsc1ccFsp-cre
+ mice also had a blunt nose, reduced eye opening, paw enlargement (Fig 1C), and dermatitis,
as reflected in repetitive scratching behavior. Repetitive scratching often led to dermatitis, and
a need to sacrifice the mouse on a humane basis. Interestingly, this was seen only in male (19
of 25, 76%) and not in female (0 of 13) mice (p<0.0001, Fisher’s exact test).
Normal mouse skin consists of a very thin surface epithelium (epidermis), a thicker connec-
tive tissue layer (dermis), and a much larger adipose tissue layer (hypodermis) (Fig 2A left). A
thin layer of striated muscle separates the skin from other structures. Tsc1ccFsp-cre+ mice dis-
played an approximate two-fold increase in the thickness of the dermis (Fig 2C, p< 0.0001 for
ventral dermis, p = 0.0005 for dorsal dermis) coupled with a more modest increase in ventral
and dorsal epidermis thickness (Fig 2B, p = 0.0009 for ventral epidermis, p = 0.09 for dorsal
epidermis). Many sections also showed a marked reduction in the hypodermis or adipose
layer. Inspection of H & E sections suggested that there was an increased number of mast cells
in the dorsal dermal layer, and chloroacetate esterase staining was performed to enable enu-
meration of mast cells (Fig 3A). There was an average 3.6-fold increase in mast cells per HPF
in the mutants (Fig 3B) in both dorsal (p = 0.0038) and ventral (p = 0.036) skin. This was not
due to repetitive scratching behavior, since that occurred only on the dorsal skin.
Given these abnormal features of the skin in the Tsc1ccFsp-cre+ mice, we hypothesized that
there would be a concordant increase in blood vessel density, as seen in both facial angiofibro-
mas and angiomyolipomas in TSC. However, using endomucin immunohistochemistry to
identify blood vessels, we found that blood vessel density was not significantly different
between normal and mutant skin on either dorsal or ventral sites, though there was a trend
toward more blood vessels in the mutant mice (Fig 3C).
As noted above, the hypodermis layer was markedly thinned in the Tsc1ccFsp-cre+ mice
(Fig 2A). Fat necrosis was seen consistently in the mutant mice in this region, and was likely a
major contributor to hypodermal atrophy (Fig 3A bottom row).
Analysis of recombination and mTORC1 activation in Tsc1ccFsp-cre+
mice skin
The Fsp-cre transgene has been reported to lead to high level recombination in mesenchymal
lineage cells including fibroblasts [10]. To define the extent of cre expression and recombina-
tion, we performed confocal microscopy of fresh-frozen OCT-embedded skin sections of the
TSC Skin Model
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Fig 1. Survival and gross skin features of Tsc1ccFsp-cre+ mice. A. Survival curve of mice of various
genotypes. Note reduced survival of Tsc1ccFsp-cre+ mice in comparison to other genotypes (p<0.0001). The
median survival of Tsc1ccFsp-cre+ mice is 338 days. Right, there was no major difference between the
survival of female and male Tsc1ccFsp-cre+ mice (p = 0.2660). The median survival of females and males is
349 days and 304 days respectively. B. Pictures of mice of various genotypes are shown. Note the loose,
TSC Skin Model
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somewhat wrinkled skin seen in the Tsc1ccFsp-cre+ mice in comparison to other genotypes. All mice shown
had age 8 months. C. Additional pictures of mice at age 1 year, with two Tsc1ccFsp-cre+ mice on left and two
Tsc1cc mice on right. Note wrinkled loose skin on abdomen, blunt nose, and larger paws of the Tsc1ccFsp-cre
+ mice in comparison to the Tsc1cc mice.
doi:10.1371/journal.pone.0167384.g001
Fig 2. Skin histology in Tsc1ccFsp-cre+ mice. A. Representative skin H&E sections are shown for mice of each genotype at 1 year of
age. All images shown are taken at 40x magnification. Top panel is dorsal and the bottom panel is ventral skin. Several layers are
indicated in selected images, including dermis, hypodermis, and muscle layers. Note the increase in the dermal thickness and marked
reduction in the hypodermis in Tsc1ccFsp-cre+ mice compared to Tsc1cc mice. B, C. Quantitation of epidermis (B) and dermis (C)
thickness is shown for control (solid circles) and Tsc1ccFsp-cre+ (solid squares) mice. Note the increase in both epidermal and dermal
thickness, which is statistically significant in all cases except control vs. mutant dorsal epidermis. n = 10–14 for each measurement; mice
had ages 8–13 months.
doi:10.1371/journal.pone.0167384.g002
TSC Skin Model
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mice, using anti-Cre and anti-pS6(S235/S236) antibodies. Although there was considerable
background staining by the anti-Cre antibody, a population of Cre+ pS6+ fibroblast cells were
clearly identified in the Dermis layer of skin of the Tsc1ccFsp-cre+ mice, and not seen in control
skin sections (Fig 4). This indicates that dermal fibroblasts are showing cre expression and
activation of mTORC1, as expected.
Fig 3. Increased mast cells and fat necrosis are seen in the skin of Tsc1ccFsp-cre+ mice. A. High power
images (400x magnification) of Tsc1cc and Tsc1ccFsp-cre+ mouse skin at age 1 year is shown. Upper panel,
chloroacetate esterase stain to highlight mast cells. Bottom panel, H&E stain showing fat necrosis, inset at
1000x. B. Quantification of mast cells per high-powered field (400x) as assessed by dermatopathologist (SG).
Mast cells are significantly increased in both dorsal and ventral skin of Tsc1ccFspCre1+ mice compared to
Tsc1cc mice. n = 3–9 for each measurement; mice had ages 8–13 months. C. Quantification of blood vessel
density per high-powered field (400x) as assessed by dermatopathologist (SG). There is a possible trend
toward more vessels in the mutant mouse skin. n = 2–4 for each measurement; mice had ages 8–13 months.
doi:10.1371/journal.pone.0167384.g003
TSC Skin Model
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Rapamycin treatment reduces dermal thickness and mast cell numbers
but does not rescue skin abnormalities to a major extent
Rapamycin is an allosteric inhibitor of mTORC1 that markedly reduces its kinase activity for
many substrates, particularly S6Kinase. It has been shown to be remarkably effective in the
treatment of a variety of TSC mouse tumor and brain models, and for a number of TSC-related
tumors [11–14]. To examine the potential benefit of rapamycin for this model, we performed a
pilot experiment, treating Tsc1ccFsp-cre+ mice with either vehicle (n = 2) or rapamycin (n = 2)
at 3mg/kg given by intraperitoneal injection 3 days per week for 4 weeks, beginning at age 3
months. Analysis of this pilot data indicated that there was a trend toward reduction of ventral
epidermal thickness in treated mice, and toward reduction in mast cell count in dorsal sections
(Fig 5). However, other measures appeared to be unaffected by treatment in this limited num-
ber of samples.
Tsc1ccFsp-cre+ skin fibroblasts show Tsc1 loss and mTORC1 activation
To confirm that recombination and loss of Tsc1 expression was occurring in skin fibroblasts
of these mice, we prepared primary skin fibroblast cultures from Tsc1ccFsp-cre+ and control
Tsc1cc mice. Genotyping confirmed the presence of the Fsp-cre allele in these cultures, and
showed that there was near complete conversion of the conditional allele to the null allele (Fig
6A). The Tsc1ccFsp-cre+ fibroblast cultures showed marked reduction of Tsc1 and Tsc2
Fig 4. Identification of Cre expression and mTORC1 activation in the skin of Tsc1ccFsp-cre+ mice. Confocal microscopy fused images (100x)
are shown with nuclear (DAPI, blue), Cre (Anti-Cre antibody, green), and pS6(S235/236) (antibody, red) are shown. Multiple cells with appearance of
fibroblasts are seen in the lower dermis of the mutant Tsc1ccFsp-cre+ mouse skin, that stain with both red and green stains (yellow, indicated by arrow
heads). Some of these cells are shown at higher magnification in the inset in the upper right corner (600x). A similar region of the control mouse skin
shows no staining.
doi:10.1371/journal.pone.0167384.g004
TSC Skin Model
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expression, as expected. Tsc1ccFsp-cre+ fibroblasts also showed constitutive activation of
mTORC1 during serum deprivation with high levels of pS6(S240/244) and some increase in
pS6K(T389), and a dramatic reduction in pAKT(S473) levels in response to serum stimulation,
consistent with previous data on signaling effects of mTORC1 activation in cells lacking Tsc1
(Fig 6B) [15–17].
Discussion
Consistent with multiple previous reports [10, 18, 19], the Fsp-cre allele used here led to target-
ing of Cre recombinase expression to fibroblasts leading to recombination and loss of Tsc1
expression in the skin fibroblasts of the Tsc1ccFsp-cre+ mice (Figs 5 and 6), and likely other tis-
sues. The mice displayed a modest phenotype for several months until a variety of tumors
developed in the male mice, and chylous ascites developed in female mice, leading to a median
Fig 5. Response of the skin of Tsc1ccFsp-cre+ mice to one month treatment with rapamycin. A. Low and high power images of Tsc1ccFsp-
cre+ mouse skin at age 1 year is shown. Upper panel, H&E stain, with dermis indicated. Lower panel, chloroacetate esterase stain highlights mast
cells. B-D. Quantification of epidermis and dermis thickness, and mast cell count per high-powered field (400x) as assessed by
dermatopathologist (SG).
doi:10.1371/journal.pone.0167384.g005
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survival of a little less than one year. The major phenotype that was seen in these mice was in
the development of the skin disorder described.
All organs of these mice were examined pathologically, with special emphasis on the kid-
neys and lungs in a cohort of Tsc1ccFsp-cre+ mice at ages 9–12 months. No evidence of kidney
angiomyolipoma or lymphangioleiomyomatosis was seen in any mouse. These observations
strongly suggest that stromal fibroblasts are not the cell of origin of these two tumors, which
are known to be closely related in terms of their genetics and pathologic features [4, 5, 20–22].
Fig 6. Analysis of fibroblast cell lines generated from the skin of Tsc1ccFsp-cre+ mice. A. PCR
genotyping analysis of 4 fibroblast cell lines derived from littermate newborn pups. The Tsc1cc cell line (cc-)
has no Cre product and shows only the Tsc1 conditional allele PCR product; the other three Tsc1ccFsp-cre+
cell lines (cc+) have both Cre PCR products and Tsc1 knock-out (k) allele products. B. Immunoblot analysis of
4 fibroblast cell lines after 24 h of serum (FBS) starvation (-) or 30 min after serum addback following serum
starvation (+). Note absent Tsc1 expression and markedly reduced Tsc2 expression by the cc+ lines;
increased pS6 and pS6K1 expression and absent pAKT expression by the cc+ cell lines.
doi:10.1371/journal.pone.0167384.g006
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Expression of melanocyte proteins, VEGFD, and Cathepsin K by these tumors suggests the
possibility that the cell of origin is derived from the neural crest [23–27]. The lack of angio-
myolipoma and lymphangioleiomyomatosis development in these mice are consistent with
that hypothesis, as well as other possibilities.
The skin abnormalities seen in all Tsc1ccFsp-cre+ mice have are not a close match to the
angiofibromas and ungual fibromas seen in TSC patients. Tsc1ccFsp-cre+ mice were shown to
have thickening of the dermis with increased numbers of fibroblasts. However, there is not a
prominent vascular component nor a marked increase in mast cells reported in human TSC
patient lesions [28]. Furthermore, there was a minimal response to rapamycin treatment in
contrast to what has been reported for TSC patients using topical rapamycin for skin treatment
[29]. This may be due in part to the differences in human vs. mouse skin components, espe-
cially the abundant hair follicles present in mouse skin. In addition, however, although it can
be predicted that dermal fibroblasts will undergo spontaneous loss of the second allele of
TSC1/TSC2at multiple sites, the distribution of angiofibromas in TSC subjects is highly cir-
cumscribed, suggesting that other factors influence the development of these lesions beyond
loss of TSC1 or TSC2. Further investigation is required.
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